» Articles » PMID: 33063927

Understanding Attitudes, Concerns, and Health Behaviors of Patients with Inflammatory Bowel Disease During the Coronavirus Disease 2019 Pandemic

Overview
Specialty Gastroenterology
Date 2020 Oct 16
PMID 33063927
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aim: The coronavirus disease 2019 (COVID-19) pandemic has led to a rapid shift in care delivery models for patients with inflammatory bowel disease (IBD); however, little is known about patient perceptions during this period. We aimed to prospectively evaluate the attitudes, concerns, and health behavior of IBD patients during COVID-19.

Methods: An online survey was sent to patients from a tertiary IBD Service. The survey included demographic information and questions about the impact of COVID-19, levels of concern caused by COVID-19, perceived risk of IBD medications, medication cessation, and care delivery preferences.

Results: Of 97 respondents (39%), 95 (98%) reported concern about the impact of COVID-19 on their health, and 43% felt their risk of contracting COVID-19 was above average; 62% reported concern about medication-induced COVID-19 risk, and 11% stopped medications because of COVID-19. Patients considered all medications to increase the risk of COVID-19 susceptibility and severity; 45% preferred telehealth while 16% preferred face-to-face clinic reviews. Preference for IBD monitoring tools in decreasing order was blood testing, stool collection, gastrointestinal ultrasound, magnetic resonance enterography, and then colonoscopy.

Conclusions: Patients with IBD are demonstrated to experience concern related to their diagnosis and medications. The insights provided by the survey are informative for a possible "second-wave" of COVID-19 and routine care, including acceptance of telemedicine, preference for non-invasive investigations, and a need for dissemination of information and education.

Citing Articles

Motivational Interviewing as a Strategy to Improve Adherence in IBD Treatment: An Integrative Review Amidst COVID-19 Disruptions.

Mercuri C, Catone M, Bosco V, Guillari A, Rea T, Doldo P Healthcare (Basel). 2024; 12(12).

PMID: 38921325 PMC: 11204356. DOI: 10.3390/healthcare12121210.


Impact of an intervention program on drug adherence in patients with ulcerative colitis: Randomized clinical trial.

Pacheco M, Sa P, Santos G, Boa-Sorte N, Domingues K, Assis L PLoS One. 2023; 18(12):e0295832.

PMID: 38150452 PMC: 10752503. DOI: 10.1371/journal.pone.0295832.


The Impact of the COVID-19 Pandemic on Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey.

Peyrin-Biroulet L, Ylanne K, Sipes A, Segovia M, Gardiner S, Cappelleri J Adv Ther. 2023; 41(2):598-617.

PMID: 38048018 PMC: 10838856. DOI: 10.1007/s12325-023-02673-0.


Identification of the informational and supportive needs of patients diagnosed with inflammatory bowel disease: a scoping review.

Norouzkhani N, Faramarzi M, Ghodousi Moghadam S, Karimi M, Shirvani J, Bahari A Front Psychol. 2023; 14:1055449.

PMID: 37251032 PMC: 10211349. DOI: 10.3389/fpsyg.2023.1055449.


Satisfaction with telemedicine-delivered inflammatory bowel disease care depends on disease activity, personality and economic factors.

Storan D, Lavelle J, Burke A, Hamzawi M, Brett-Kilmurray O, De Dominicis N Frontline Gastroenterol. 2023; 14(2):132-137.

PMID: 36818801 PMC: 9933585. DOI: 10.1136/flgastro-2022-102198.


References
1.
Goodsall T, Han S, Bryant R . Understanding attitudes, concerns, and health behaviors of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol. 2020; 36(6):1550-1555. PMC: 7675463. DOI: 10.1111/jgh.15299. View

2.
Danese S, Sands B, Ng S, Peyrin-Biroulet L . The day after COVID-19 in IBD: how to go back to 'normal'. Nat Rev Gastroenterol Hepatol. 2020; 17(8):441-443. PMC: 7263180. DOI: 10.1038/s41575-020-0322-8. View

3.
Tinsley A, Navabi S, Williams E, Liu G, Kong L, Coates M . Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018; 25(2):369-376. DOI: 10.1093/ibd/izy243. View

4.
Toruner M, Loftus Jr E, Harmsen W, Zinsmeister A, Orenstein R, Sandborn W . Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134(4):929-36. DOI: 10.1053/j.gastro.2008.01.012. View

5.
Brenner E, Ungaro R, Gearry R, Kaplan G, Kissous-Hunt M, Lewis J . Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020; 159(2):481-491.e3. PMC: 7233252. DOI: 10.1053/j.gastro.2020.05.032. View